Table 1 The demographics and change of CKD stages of 92 HBV patients assigned to be treated with LdT or ETV
LdT (n = 46) | ETV (n = 46) | P-value | |
|---|---|---|---|
Age (mean ± SD) | 46.3 ± 13.4 | 51.3 ± 11.5 | 0.06 |
Sex (M) (%) | 35 (76.1) | 35 (76.1) | 1 |
CKD stages (%) | 0.31 | ||
CKD 1 | 23 (50.0) | 20 (43.5) | |
CKD 2 | 19 (41.3) | 24 (52.2) | |
CKD 3 | 4 (8.7) | 1 (2.2) | |
CKD 4 | 0 (0) | 1 (2.2) | |
Diabetes (%) | 11 (23.9) | 8 (17.4) | 0.44 |
Hypertension (%) | 15 (32.6) | 8 (17.4) | 0.09 |
Nephrotoxic agents (%) | 13 (28.3) | 10 (21.7) | 0.47 |
Cyclophosphamide (%) | 1 (2.2%) | 1 (2.2%) | |
NSAID (%) | 4 (8.8%) | 1 (2.2%) | |
HBV DNA (log IU/mL) (IQR) | 6.6 (1.9) | 6.2 (2.5) | 0.93 |
HBe Ag (+) (%) | 29 (63.0) | 28 (60.1) | 0.57 |
eGFR (± SD) (mL/min/1.73 m2) | |||
Baseline | 94.3 ± 28.3 | 93.1 ± 26.1 | 0.87 |
Year 3 | 104.0 ± 31.2 | 85.5 ± 25.1 | 0.005 |
Year 4 | 104.0 ± 28.8 | 87.7 ± 24.8 | 0.04 |